RecruitingNCT06596746

Neurodegenerative Diseases Progression Markers (MARKERS-NDD)

Neurodegenerative Diseases Progression Markers (MARKERS-NDD): a Real-world Data Longitudinal Prospective Study

Sponsor

Casa di Cura San Raffaele Cassino

Enrollment

600 participants

Start Date

Sep 9, 2024

Study Type

OBSERVATIONAL

Conditions

Cognitive Impairment Dementia Multiple System Atrophy Movement Disorders Amyotrophic Lateral Sclerosis Alzheimer Disease Parkinson Disease Corticobasal Degeneration Lewy Body Disease Neurodegenerative Diseases Frontotemporal Lobar Degeneration TDP-43 Proteinopathies Tauopathies Atypical Parkinsonism Synucleinopathies Supranuclear Palsy, Progressive Iron Overload Neurodegeneration With Brain Iron Accumulation (NBIA)

Summary

MARKERS-NDD is a prospective, observational, longitudinal study, which aims to collect data from patients affected by neurodegenerative diseases (NDD) followed longitudinally for routine examinations performed as part of normal clinical practice. Data collected from clinical evaluations, movement analysis, brain imaging, neuropsychological and electroencephalographic assessments, blood chemistry tests will be analysed to carry out statistical investigations and predictive analyses, also using artificial intelligence systems, which allow the identification of new early markers of diagnosis and prognosis of neurodegenerative diseases.

Eligibility

Min Age: 10 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting data and tracking disease progression in patients with Parkinson's disease, related movement disorders, and dementia conditions, to identify markers (biological signals) that show how these diseases progress over time. **You may be eligible if...** - You have been diagnosed with Parkinson's disease, Multiple System Atrophy, Progressive Supranuclear Palsy, or Essential Tremor, OR - You have been diagnosed with Lewy Body Dementia, Alzheimer's disease, mild cognitive decline, or memory complaints - You are willing to participate and sign an informed consent **You may NOT be eligible if...** - There are no specific age or severity restrictions - You are unable to complete the required assessments Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERObservation

In MARKERS-NDD up to 600 participants will be enrolled and followed longitudinally once identified, over the course of 1-10 years

Locations(1)

San Raffaele Cassino

Cassino, Frosinone, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06596746

Related Trials

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

NCT06585787288 locations

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)

NCT07011745140 locations